FDA orders DMD trial halt, raising questions about a whole class of promising drugs
Dyne Therapeutics’ stock took a nasty hit this morning after the biotech put out word that the FDA had slapped a clinical hold on their top program for Duchenne muscular dystrophy. And now speculation is bouncing around Biotwitter that there could be a class effect at work here that would implicate other drug developers in the freeze.
Dyne execs didn’t have a whole lot to say about why the FDA sidelined their IND for DYNE-251 in DMD while “requesting additional clinical and non-clinical information for” the drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 142,800+ biopharma pros reading Endpoints daily — and it's free.